Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Inventory (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Inventory for 14 consecutive years, with $143.1 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 4.59% to $143.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $143.1 million through Dec 2025, up 4.59% year-over-year, with the annual reading at $143.1 million for FY2025, 4.59% up from the prior year.
  • Inventory hit $143.1 million in Q4 2025 for Ani Pharmaceuticals, down from $146.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $148.0 million in Q3 2024 to a low of $59.9 million in Q1 2021.
  • Historically, Inventory has averaged $110.0 million across 5 years, with a median of $106.0 million in 2022.
  • Biggest five-year swings in Inventory: soared 57.44% in 2022 and later fell 1.06% in 2025.
  • Year by year, Inventory stood at $89.4 million in 2021, then rose by 17.79% to $105.4 million in 2022, then rose by 5.54% to $111.2 million in 2023, then grew by 23.01% to $136.8 million in 2024, then increased by 4.59% to $143.1 million in 2025.
  • Business Quant data shows Inventory for ANIP at $143.1 million in Q4 2025, $146.5 million in Q3 2025, and $138.3 million in Q2 2025.